Pharmacometrics: A Competitive Advantage in Improving R&D for Companies of All Sizes

Pharmacometrics—the use of modeling and simulation to support drug development and assessment decisions—has been in use for more than two decades. Today, however, the urgent need for improved R&D productivity within the pharmaceutical sector has highlighted the broader applications of this evolving science.

Pharmacometrics is becoming a competitive advantage for drug sponsors seeking a faster development process and more efficient research methodologies. Sponsors can use it as a form of “virtual reality” to envision the development path and avoid costly and unproductive action.

Long the purview of large pharmaceutical companies with the necessary computational power and crossfunctional expertise in-house, pharmacometrics holds promise for small and midsized companies, as well. Experienced partners offer smaller companies the benefits of pharmacometrics without the cost of having to develop and manage such specialized resources themselves.

Here, we explore the use and value of pharmacometrics in the drug life cycle, trends in best practices and counsel for companies requiring high-level pharmacometrics expertise without the cost of building an entire pharmacometrics function.

Click here to read our pharmacometrics white paper